Post-Operative Pain and Opioid Reduction Trial After Bunionectomy (NCT05411861) | Clinical Trial Compass
CompletedPhase 2
Post-Operative Pain and Opioid Reduction Trial After Bunionectomy
United States73 participantsStarted 2022-06-14
Plain-language summary
This is a Phase 2b, randomized, double blind, placebo and active controlled study with an Ascending Dose Stage and an optional Dose Expansion Stage in subjects undergoing bunionectomy.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Be willing and able to sign the informed consent form (ICF) prior to study participation
* In the medical judgment of the Investigator, be a reasonably healthy adult 18 - 75 years of age, inclusive, and ASA Class I or II at the time of randomization
* Plan to undergo an elective primary unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia, without collateral procedures or additional surgeries
* Have a BMI ≤ 39 kg/m2
Exclusion Criteria:
* Previous unilateral simple bunionectomy
* Has a planned concurrent surgical procedure that may impact pain scores, rescue medication use, or ability to fulfill the requirements of the protocol
* Concurrent painful condition
* Active skin disease or other clinically significant abnormality at the anticipated surgical site that could interfere with the planned surgery
* Known hypersensitivity or known allergy, as determined by the Investigator, to the ingredients (i.e., excipients) of the study drug or any peri- or postoperative medications used in this study
* History or clinical manifestation of significant medical, neuropsychiatric, or other condition that could preclude or impair study participation or interfere with study assessments
* History of malignant hyperthermia or glucose-6-phosphate dehydrogenase deficiency
* History or evidence of impaired liver function (e.g., ALT \> 3 × upper limit of normal \[ULN\] or total bilirubin \> 2 × ULN), active hepati…